This information was released for public disclosure on February 25, 2013 at 12.00 am CET. Press release as PDF
CellaVision today announced that the Company has signed a distribution agreement with global healthcare company, Abbott, to market and distribute CellaVision's leading-edge digital microscopy products to the hematology market in Europe and the countries in former Soviet Union (CIS). The non-exclusive agreement comprises most European countries*, and is effective from February 25, 2013.
"I am very pleased to enter into this agreement with Abbott in Europe. By cooperating with strategic partners who have a high market presence and an extensive sales and support network, CellaVision anticipates further business expansion. By adding yet another distributor to our sales channels, we have now given more clinical laboratories in Europe access to our digital microscopy products, regardless of their hematology vendor", said Yvonne Mårtensson, CellaVision CEO.
Europe is one of CellaVision's major growth markets. The transition from manual microscopy to CellaVision's method has been in progress for a few years in the European countries. In 2012 Europe accounted for 33 percent of the company's total sales.
* In 2012 separate agreements were signed for Sweden, Norway and Denmark. These agreements differ from the European distribution agreement in that CellaVision is responsible for installation and support.
For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82 | Email: firstname.lastname@example.org
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In most countries sales are via global partners. Products are sold directly in the Nordic countries and via subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.
This information is disclosed by CellaVision AB (publ) pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public disclosure on February 25, 2013 at 12.00 am CET.